In the latest reporting period of Q1'26, AbbVie (ABBV) reported a Return on Sales (ROS) of 11.21%. This represents a significant decrease compared to the previous quarter's margin of 20%. The ROS data from Q2'23 to Q1'26 exhibits notable volatility, characterized by a sharp decline to a low of -10.98% in Q4'24 followed by a strong recovery. While the margin reached a peak of 22.08% at the beginning of the period in Q2'23, the overall trend has been inconsistent, with the most recent three quarters showing a downward trajectory from the 20% mark seen in Q4'25.